• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Keryx Biopharmaceuticals Inc

+ Add to Watchlist


9.979 EUR 0.043 0.43%

As of 10:45:49 ET on 04/17/2014.

Snapshot for Keryx Biopharmaceuticals Inc (KYX)

Open: 9.855 Day's Range: 9.855 - 10.250 Volume: 0
Previous Close: 10.022 52wk Range: 5.114 - 14.673 1-Yr Rtn: +73.55%

Stock Chart for KYX

No chart data available.
  • KYX:GR 9.979
  • 1D
  • 1M
  • 1Y
Interactive KYX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KYX

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.6310
Est. PEG Ratio -
Market Cap (M EUR) 907.21
Shares Outstanding (M) 90.91
30 Day Average Volume 184
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KYX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for KYX

Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.

Ron BentsurChief Executive OfficerJames F OlivieroCFO/Treasurer/Secretary
Gregory P Madison "Greg"Exec VP/COOBrian R AdamsVP/General Counsel
More Company Profile & Key Executives for KYX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Links
sec ||= nil